Amgen scores pediatric FDA approval for Nplate in immune thrombocytopenia
Amgen’s Nplate (romiplostim) has been approved by the US Food and Drug Administration (FDA) for the treatment of pediatric patients
Continue readingCoverage of Global Pharma Industry News
Amgen’s Nplate (romiplostim) has been approved by the US Food and Drug Administration (FDA) for the treatment of pediatric patients
Continue readingFresenius Kabi has launched Omegaven (fish oil triglycerides) injectable emulsion in the US, which helps pediatric patients suffering from parenteral
Continue readingMillendo Therapeutics, a clinical-stage biopharma company engaged in developing drugs for orphan endocrine diseases, has wrapped up a previously announced
Continue readingNovartis breast cancer drug Kisqali (ribociclib) plus endocrine therapy has succeeded in extending progression-free survival (PFS) compared to only endocrine
Continue readingMirum Pharmaceuticals, a clinical stage pharma company in San Diego, has raised $120 million in a Series A funding round
Continue readingGilenya EC approval : The European Commission (EC) has expanded the approval of Novartis multiple sclerosis drug Gilenya (fingolimod) to
Continue readingPfizer adalimumab biosimilar update : Pfizer and AbbVie have signed licensing agreements to resolve all global intellectual property (IP) matters
Continue reading